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Abstract
Background: Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the
principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of
metastasis.
Methodology/Principal Findings: Lack of a suitable animal model has so far hampered analysis of metastatic progression.
We have examined c-MYC for its ability to induce metastasis in a C-RAF-driven mouse model for non-small-cell lung cancer.
c-MYC alone induced frank tumor growth only after long latency at which time secondary mutations in K-Ras or LKB1 were
detected reminiscent of human NSCLC. Combination with C-RAF led to immediate acceleration of tumor growth,
conversion to papillary epithelial cells and angiogenic switch induction. Moreover, addition of c-MYC was sufficient to
induce macrometastasis in liver and lymph nodes with short latency associated with lineage switch events. Thus we have
generated the first conditional model for metastasis of NSCLC and identified a gene, c-MYC that is able to orchestrate all
steps of this process.
Conclusions/Significance: Potential markers for detection of metastasis were identified and validated for diagnosis of
human biopsies. These markers may represent targets for future therapeutic intervention as they include genes such as
Gata4 that are exclusively expressed during lung development.
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Introduction
Metastasis is a complex multistep process by which cells in the
primary tumor become able to enter and leave the vasculature,
settle at distant sites and eventually grow to macroscopic
secondary tumors [1]. It is generally thought that metastatic
conversion is a mutation driven process. A number of genes and
gene products have been identified that positively or negatively
affect the probability of established human tumor cell lines to
metastasize [2,3,4]. Gene products include growth factor receptors
and elements of their intracellular signal transduction cascades.
Regulators of cell polarity represent a second class of genes that
may promote metastasis [5,6]. By use of a mouse lung cancer cell
line, Lewis lung carcinoma (LLC), a third category of metastasis
regulators has recently been described that highlighted the
importance of inflammation as a driving force [7]. Moreover,
candidate metastasis-inducing or -suppressing genes also include
genes encoding micro RNAs that regulate sets of genes associated
with proliferation, invasion or migration [8,9].
While work with human tumor cell lines in mice has been
enlightening, lack of knowledge about their repertoire of cancer
genes as well as the inability to study the kinetics of spontaneous
tumor progression in these models limit their usefulness. We have
therefore established a mouse model for human non–small-cell
lung cancer (NSCLC) in which premalignant adenoma is induced
by a RAF transgene specifically expressed in lung alveolar type II
epithelial cells [10]. NSCLC is the most frequent human lung
cancer and the major cause of death from cancer in man.
Generation of compound mice that carry in addition to RAF other
transgenes that encode proteins modulating signaling pathways
frequently altered in human NSCLC allowed us to unravel two
key steps in the process of metastasis, induction of the angiogenic
switch and progression to micrometastasis associated with
reprogramming of intestinal selector genes [11]. b-catenin was
identified as the critical switch inducer for both steps and also
promoted invasive growth [11].
As 50% of human NSCLC carry mutations in genes that
encode activators of the mitogenic cascade (RAS-RAF-MEK-
ERK) [12] and this cascade is known to induce a target gene of ß-
catenin, c-MYC [13], we decided to directly examine the ability of
c-MYC to promote tumor progression in our RAF-driven murine
lung cancer model. Moreover MYC was a candidate because it
was known to affect reprogramming in tumors based on our earlier
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findings of RAF/MYC cooperation in the murine hematopoietic
system [14,15]. In humans, amplification and rearrangements of
Myc genes were found in a fraction of NSCLC [16]. Several
groups have begun to evaluate c-MYC in mouse models of
NSCLC. Endogenous c-MYC is involved in non metastatic K-
Ras-induced NSCLC as was shown by use of a dominant negative
c-MYC mutant [17]. Inducible expression or function of
transgenic c-MYC demonstrated cooperation with mutant K-
Ras in tumor progression to various degrees [18,19] but neither
model gave rise to metastasis. Here we show that constitutive or
inducible expression of c-MYC in addition to C-RAF in type II
cells is sufficient to rapidly induce metastasis to liver and lymph
nodes. Combining c-MYC and C-RAF transgenes caused
appearance of a phenotypic switch from cuboidal to alveolar
papillary/columnar epithelial cells (APECs) that are the most
rapidly growing tumor cells and also predominate in liver
metastasis. Moreover c-MYC induces production of VEGF by
tumor cells leading to tumor vascularisation with unusual vessels
that are mosaics containing PECAM-1 positive and PGP 9.5
positive endothelial cells. PGP 9.5 was previously known as a
marker of immature neuroendocrine cells [20]. Metastatic
conversion by c-MYC can be reconstructed in cell culture by
using non-metastatic A-549 NSCLC cells and infection with a
MYC transducing retrovirus.
Results
c-MYC cooperates with C-RAF in causing cancer related
death
To test whether C-RAF and c-MYC cooperate in transformation
of lung epithelial type II cells in vivo, SpC-C-RAF BxB mice were
crossed with SpC-c-MYC transgenic mice. Observation for a period
of$2 years demonstrated accelerated death in compound (SpC-C-
RAF BxB/SpC-c-MYC) mice (Figure 1A) although the degree of
acceleration was less than seen previously in the hematopoietic
system with MYC/RAF retroviruses [21]. Nevertheless, compound
mice had a median latency that significantly differed from single
SpC-c-MYC transgenic mice by log-rank analysis. Histological
examination at different time points revealed that single transgenic
mice differed in tumor free survival. Whereas SpC-C-RAF BxB or
compound mice were uniformly tumor positive at two weeks of age,
SpC-c-MYC single transgenic mice developed tumors late and with
incomplete penetrance indicating that c-MYC is not rate limiting
for proliferation of type II cells and/or that responsive cells are
eliminated by apoptosis (Figure 1B).
Premalignant lesions in SpC-c-MYC single transgenic
mice
Before onset of frank malignancy in SpC-c-MYC single
transgenic mice clusters of pleomorphic cells are detected in the
lungs that are potential sources for metastasis initiating cells
(MICs) (Figure 1C). Intriguingly, pleomorphic clusters in lungs
from long term survivors were often diminished or completely
absent (data not shown). In order to characterise these potential
premalignant lesions, expression of genes regulating proliferation
and lung development was examined by immunostaining (Figure
S1). As expected, strong nuclear c-MYC and expression of C-RAF
at low endogenous levels was detected in these clusters (Figure S1).
Pleomorphic cells proliferate as judged from PCNA staining and
have a high rate of apoptosis which is presumably responsible for
their lack of hyperplastic expansion (Figure S1 and Figure S2)
which also sets these lesions apart from atypical adenomatous
hyperplasia (AAH). Markers of type II pneumocytes are
maintained in the c-MYC positive foci including Gata6 which
drives TTF-1 expression [22]. In contrast Gata4 and its target
gene mucin are not expressed (Figure S1). Of the downstream
effectors of the Gata6-TTF-1 cascade only pro SP-C but not
CCSP is expressed at low levels when compared to type II
pneumocytes outside of the clusters demonstrating absence of
bronchio alveolar stem cells (BASCs) (Figure S1) [23]. c-MYC
expression in pleomorphic clusters is associated with induction of
proliferation and apoptosis (Figure S1 and Figure S2). In fact by
using a doxycycline (DOX) inducible c-MYC transgene, we
observed massive apoptosis after one day induction and extensive
loss of lung tissue four weeks after induction (Figure S3A–S3C).
Prolongation of the induction period led to formation of
pleomorphic clusters and isolated papillary lung tumors (Figure
S3D–S3E).
We next looked at Aquaporin 5 expression that is shared
between type I and type II pneumocytes [24] and found it to be
maintained in pleomorphic clusters (Figure S1). To gain further
insights into progenitor features of these cells, a series of markers of
developmental pathways was examined. These include HNF-3ß,
Sox9 [20], and factors that are notoriously involved in stem or
progenitor cells such as Bmi-1 [25], ß-catenin and Id2 [20]. All of
these genes were found to be expressed (Figure S1). Id2 has been
described to mediate Myc signalling in conjunction with a
retinoblastoma protein [26]. We conclude that cells in the high
c-MYC expressing clusters have progenitor cell features but differ
from BASCs.
Rescue and accelerated growth of c-MYC transformed
type II pneumocytes by C-RAF
In contrast to lungs of SpC-c-MYC single transgenic mice that
only develop premalignant lesions, tumor nodules in lungs of
compound or late SpC-c-MYC single transgenic mice were rapidly
expanding and frequently contained macroscopic tumors with
columnar cells that were absent in SpC-C-RAF BxB–driven
adenomas (Figure 1C). Several lines of evidence indicate that
columnar cells arise from cuboidal cells in compound mice. First,
the tumor incidence at two weeks and two months of age is the same
for SpC-C-RAF BxB single and SpC-C-RAF BxB/SpC-c-MYC
compound mice (Figure 2A). Second, columnar cells mostly arise
within cuboidal tumor foci (Figure S4A). Finally, columnar cells can
be rapidly and frequently induced in vivo by DOX treatment of
triple transgenic compound mice (SpC-C-RAF BxB/SpC-rtTA/
tet-O-c-MYC) (Figure S4B and S4C). To test reversibility of c-MYC
transgene expression DOX was removed one week after induction
for a period of four weeks (Figure S4D). Histological analysis of the
imaged lung tumor showed persistence of columnar cells in the
center of one remaining tumor that otherwise displays a cuboidal
phenotype (Figure S4D). Extension of the observation period after
DOX removal to 10 weeks demonstrated elimination of columnar
cells in tumors of all mice analyzed (data not shown). Comparison of
tumor burden between continuously induced mice and mice that
were taken off DOX for ten weeks after a four week induction
period did not show significant differences (data not shown). These
data suggest that a ‘‘shock from oncogene withdrawal’’ –effect [27]
is responsible for the disappearance of APECs although reversibility
of the MYC-induced cuboidal to columnar phenotypic switch is an
alternative possibility.
Papillary tumors grow faster than cuboidal tumors of both
genotypes. Consistently the fraction of PCNA positive, pro SP-C
expressing cells was higher in papillary tumors (Figure 2B). Similar
data were obtained by BrDU and Ki67 labeling (Figure 2C–2E).
As expected from the proliferation data, tumor volumes increased
most rapidly in papillary tumors of compound mice (Figure 2F). To
further characterize columnar cells that are the hallmarks of
NSCLC, Metastasis, RAF/MYC
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advanced adenocarcinoma, we typed them for lineage and
progenitor cell markers as in the case of the pre-malignant lesions
in SpC-c-MYC single transgenic mice. Similar to pleomorphic
clusters, columnar cells in early tumor foci from compound mice
expressed progenitor cell markers (Figure S5A). A major difference
however was the high level of C-RAF expression from the transgene
which mediates rescue of cryptic c-MYC transformants from
apoptosis (Figure S2A and S2B) leading to expansion of early tumor
foci. In contrast, pleomorphic clusters in compound mice were
similar to those in lungs of SpC-c-MYC single transgenic mice in
terms of apoptosis rate (data not shown). Expression of progenitor
cell markers in tumor foci of compound mice also differ in Id2
expression at late tumor stages when positive cells were very rare
(Figure S5B). These data are consistent with reports of a tumor
suppressor function of Id2 in the intestinal epithelium where it
drives differentiation [28]. A third difference relates to homogeneity
of transgene expression.Whereas c-MYC expression was uniform in
all pleomorphic clusters, C-RAF and c-MYC transgene expression
in columnar tumor foci was heterogeneous and decreased at late
stages (Figure S5B) suggesting fluctuation of gene expression [29].
Finally, as in the case of pleomorphic clusters and in SpC-C-RAF
BxB adenomas [30], BASCs were not detected at early or late stages
in compound tumors (Figure S5A and S5B).
c-MYC promotes tumor progression concomitant with
angiogenesis in the absence of epithelial mesenchymal
transition (EMT)
In compound mice tumor acceleration was evident histologi-
cally at all ages analyzed with frequent noninvasive macroscopic
lung tumors which were absent in SpC-C-RAF BxB single
transgenic mice (Figure 1C bottom panels). Macroscopic lung
tumors generally were of the papillary type and classified as
adenocarcinoma. In rare cases (2 in 50 cases for each genotype) we
found papillary tumors occluding bronchioles and examples of
desmoplasia in compound and SpC-c-MYC single transgenic
mice, additional features that are reminiscent of human NSCLC
pathology (Figure 1D–1F).
c-MYC has been reported to induce angiogenesis [31].
Significantly increased levels of blood and lymph vessels were
detected in lung tumors of compound and SpC-c-MYC single
transgenic mice (Figures S6A–C). The mechanism of angiogenic
switch induction by c-MYC does not involve interference with E-
cadherin expression in contrast to our earlier findings highlighting
ß-catenin [11] as no nuclear ß-catenin was detected (Figure S5C).
Moreover mast cells that are required for Myc-induced angiogen-
esis in pancreatic island tumors ([17] are absent from lung
adenocarcinomas in mice of both genotypes (data not shown).
Instead VEGF expression was detected in tumor cells of lung
tumors from SpC-c-MYC single transgenic or compound mice
(Figure S7A). Myc is also able to induce VEGF in human A-549
and mouse MLE-15 NSCLC cells in culture (Figure S7B). The
combined data suggest that Myc induces angiogenesis by up-
regulation of VEGF in NSCLC cells.
A striking observation was made when we explored potential
neuroendocrine features of our NSCLC by staining with PGP 9.5.
PGP 9.5 is an immature neuroendocrine marker and a candidate
tumor marker for human NSCLC where it is expressed in tumor
cells from .70% of stage II and IIIA tumors [32]. In our NSCLC
model, the bulk of tumor cells are negative for this deubiquitinat-
ing enzyme at all stages independent of genotypes (data not
shown). Instead, staining seems to mark vessels in the primary
tumors of SpC-c-MYC single transgenic and compound mice
(compare Figure S6D). In fact co-staining of tumor sections with
PGP 9.5 and PECAM-1 showed colocalisation of these markers in
the same vessels (Figure S6E). In order to examine whether PGP
9.5 is a marker of pathological angiogenesis, we also stained wild
type lung sections where staining was found exclusively in large
vessels but not in capillaries (Figure S6E) in line with a recent
publication showing expression of PGP 9.5 in human carotid
arteries [33]. Our findings are the first report regarding
occurrence of such endothelial cells in the tumor vasculature.
The angiogenic switch was presumably not accompanied by
typical epithelial mesenchymal transition (EMT) at the tumor
edges as we did not detect cells doubly positive for pro SP-C and
vimentin or pro SP-C and N-cadherin (Figure S8B). Moreover E-
cadherin junctions of columnar cells in tumor remained intact
(Figure S8A). Consistently we did not observe invasive fronts in
papillary tumors (Figure 1C). Instead isolated groups of tumor cells
were found in the vicinity of the primary tumors reminiscent of
collective migration [34] (Figure 1C).
Long latency tumors in SpC-c-MYC mice are positive for
K-Ras or LKB1 mutations
As the kinetics of tumor development was delayed in SpC-c-
MYC mice as compared to SpC-C-RAF BxB or compound mice
and the number of late tumors per lung was lower (Figure 3A) we
searched for secondary mutations. Toward this aim, a panel of
genes (Text S1) that are frequently altered in human NSCLC was
examined in a random collection of tumors from ten mice that led
to the identification of frequent point mutations in K-Ras and
LKB1 genes (Figure 3B). Most K-Ras mutations were in exon 1 and
were heterozygous. There was one case of an exon 2 mutation
(Figure 5B) and in three cases no mutations were found in K-Ras or
any other genes in the panel except LKB1 (Figure 3B). In fact
mutations in exon 6 of this tumor suppressor that is mutated in
34% of human NSCLC [35] were found in each of three K-Ras
negative SpC-c-MYC lung tumors (Figure 3B). Only in one case
were LKB1- and K-Ras- mutations found to coexist. In this example
a different mutation of LKB1 was observed which was present on
both alleles (Figure 3B). In all other instances, K-Ras mutations or
presence of oncogenic C-RAF were mutually exclusive with LKB1
mutation (Figure 3B). This finding may suggest that K-Ras/C-
Figure 1. c-MYC cooperates with C-RAF in tumor growth. (A) Kaplan-Meier plot for SpC-C-RAF BxB (n = 24), SpC-c-MYC (n = 52), compound
(n = 35) and wild-type (n = 28) littermate control mice. Log-rank analysis for percent survival for compound mice vs SpC-C-RAF BxB =p.0.05; SpC-C-
RAF BxB vs SpC-c-MYC=p,0.0001; compound mice vs SpC-c-MYC=p,0.0001. n: number of animals. (B) Tumor incidence in SpC-C-RAF BxB (n = 51),
SpC-c-MYC (n = 30), compound mice (n = 109) and wild-type littermate control mice (n = 58). Log-rank analysis for tumor free survival for SpC-C-RAF
BxB vs SpC-c-MYC=p,0.0001; compound mice vs SpC-c-MYC=p,0.0001; wild type vs SpC-c-MYC=p,0.0001. n: number of animals. (C) Kinetics of
tumor progression. Representative lung tumour sections stained with haematoxylin and eosin (H&E). The yellow box and arrows highlights cuboidal
cell adenoma (inset) in SpC-C-RAF BxB mice; the red box and arrows indicates pleomorphic cells (inset) in SpC-c-MYC mice and the white boxes show
a columnar cell adenoma (inset) in compound mice. For evaluation of invasiveness at the tumour-stroma interface, the boxed areas of the third panel
are magnified in the bottom panel. Genotypes and ages of mice as indicated. Isolated small tumor cell clusters around the main tumor were indicated
with red arrows. Scale bar: 100 mm. (D, E) H&E staining of paraffin embedded lung sections from compound (D) and SpC-c-MYC single transgenic (E)
mice showing papillary tumors in bronchioles. Age of mice as indicated. (F) Desmoplastic progression of lung tumors from a compound mouse. Age
of mice as indicated. Scale bar, 100 mm.
doi:10.1371/journal.pone.0006029.g001
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Figure 2. C-RAF and c-MYC cooperate in lung tumor acceleration but not in tumor incidence. (A) Tumor incidence in SpC-C-RAF BxB
(blue open squares) and compound mice (red open triangle). Each symbol represents one lung. Values were normalised for lung size to compensate
for age differences. There is no significant difference between the means. (B) Percentage of pro SP-C positive cells that are PCNA positive. Values
represent SD of the mean. Genotypes and tumor categories are indicated as follows: SpC-C-RAF BxB cuboidal (blue open squares), compound
cuboidal (red open squares) and compound columnar (red open circles). Each symbol represents one tumor. (C) Two weeks and two months old
mice were injected daily with BrDU during one week and chased for one day. Paraffin embedded lung sections from SpC-C-RAF BxB single transgenic
and compound mice were double stained for BrDU (green) and Ki67 (red) to identify cells in cycle. Dapi staining highlights lung tumors. Scale Bar:
100 mm. (D, E) Percentage of BrDU and Ki67 positive cells in tumors from both genotypes at different ages. 30 tumors from 3 mice were analysed per
genotype. Values represent SD of the mean. (F) Tumor volume was computed by measuring tumor area assuming spherical shape of tumors.
Symbols represent individual tumors. Each column represents one mouse. Genotypes and tumor categories are as described in B. All the tumors from
each category were compared between genotypes. Values represent SD of the mean. Statistical differences between groups as indicated. ns: Not
significant
doi:10.1371/journal.pone.0006029.g002
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RAF signaling in type II cells may normally lead to inactivation of
this tumor suppressor. A similar relationship was found between K-
Ras mutations and presence of oncogenic C-RAF, consistent with
the mutually exclusive pattern of RAF and RAS mutations in
human tumors [36] [37] (Figure 3B).
Myc is sufficient to induce metastasis
As we have previously seen progression to micrometastasis in
SpC-C-RAF BxB mice in which we provoked angiogenesis by
ablation of E-cadherin, we examined mice for metastasis at
different ages. Surprisingly multiple macroscopic liver- (Figure 4A
and 4B) and lymph node- metastases (Figure 4C) were observed as
early as ten months of age in compound (SpC-C-RAF BxB/SpC-
c-MYC) and SpC-c-MYC single trasngenic animals. Compound
mice developed metastasis significantly earlier, at higher incidence
than SpC-c-MYC single transgenic mice (Figure 5A). Whereas in
lymph nodes macro and micro metastasis were seen, only macro
metastases were found in the liver. Lymph node and liver
metastasis were independent events as were macro- and micro-
metastasis suggesting that metastasis initiating cells (MICs) may
Figure 3. Long latency lung tumors from SpC-c-MYC single transgenic mice frequently carry K-Ras and LKB1 mutations. (A) Tumor
incidence per lung in SpC-c-MYC mice as a function of age. Animal numbers are 17 for 2 months, 10 for 6–10.5 months and 15 for 13–17 months.
Each symbol represents an individual lung. Note that the ordinate is foci/cm2 as opposed to mm2 in Figure 2. (B) Occurrence of K-Ras and LKB1
mutations in primary lung tumors. 10 randomly picked tumor positive mice were examined for a panel of candidate genes (EGFR, K-Ras, B-RAF, C-RAF,
p53, Pi3K, PTEN, Akt and LKB1). Shown here are data for K-Ras and LKB1, the only genes of the panel in which mutations were found. Zygosity is as
indicated. Individual mice are listed by ID numbers to facilitate comparison between tables.
doi:10.1371/journal.pone.0006029.g003
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Figure 4. Macrometastases in liver and lymph nodes of SpC-c-MYC single transgenic and compound mice. (A) Inspection of liver
metastasis (left) from a SpC-c-MYC single transgenic mouse. A normal liver (right) from a non-metastatic SpC-C-RAF BxB single transgenic mouse. (B)
H&E staining of paraffin embedded liver sections from SpC-c-MYC and compound mice. Representative sections of papillary and cystic metastases are
shown. Boxed areas are shown at higher magnification. Ages and genotypes as indicated. Scale bar: 100 mm. (C) Staining of liver and lymph node
metastases from compound mice for markers as indicated. Metastases from SpC-c-MYC mice were indistinguishable when compared with compound
mice for same markers. Circled areas in lymph nodes mark metastasis (M). Scale bar: 100 mm.
doi:10.1371/journal.pone.0006029.g004
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Figure 5. Summary of liver and lymph node metastases and their mutation status. (A) Summary of metastasis pattern for SpC-c-MYC
single transgenic and compound mice. Animals are listed individually by ID number and grouped according to genotype. The median age of onset of
metastases between the groups is significant (p = 0.03). (B) Absence of K-Ras mutation in macrometastasis of RAF/MYC and RAS/MYC lung tumors.
n.m: no metastasis. n.d.: not done. D: Deletion. - : Negative.
doi:10.1371/journal.pone.0006029.g005
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differ for each category (Figure 5A). Besides SpC-c-MYC single
transgenic mice, DOX inducible expression of c-MYC which
rapidly gives rise to papillary lung tumors on the C-RAF BXB
background (Figure S4) was examined for generation of metastasis.
These mice developed lung tumors (Figure S9A) and liver
metastasis (Figure S9C and 9D) made up of columnar cells.
Consistent with the frequency of metastasis in constitutive mice, in
a cohort of 10 inducible compound mice that were induced 11–12
months, one mouse developed macroscopic liver metastastasis and
a second animal was positive for micro metastasis in a regional
lymph node (Figure S9B). A cohort of age-matched control
(uninduced) mice that were 14–17 months old did not show
metastasis (data not shown). Similar to constitutive mice, sections
from liver metastasis of inducible compound mice (Spc-C-RAF
BxB/SpC-rtTA/tet-O-c-MYC) were positive for pro SP-C and
pan-cytokeratin (Figure S9E and S9F). In contrast to constitutive
mice, liver metastasis in inducible compound mice provoked a
pronounced stromal response that separates tumor tissue from
normal liver (Figure S9D). Notably, in this stroma-rich border area
isolated clusters of tumor cells that were positive for pan-
Cytokeratin or pro SP-C were present (Figure S9E and S9F)
consistent with invasion by collective migration [34]. Upon
examination of the mutational status of K-Ras, an exon 1mutation
was found in primary lung tumors and corresponding liver
metastasis (data not shown).
If acute expression of c-MYC is sufficient for metastatic
conversion then introduction into non-metastatic NSCLC cells
should generate metastatic clones. To test this possibility we
employed human A-549 cells. A high c-MYC expressing A-549
cell clone (A-549 J5-1) (Figure 6A) was injected subcutaneously
into immunodeficient Rag12/2 mice. The incidence (Figure 6B)
and rate of local tumor growth (Figure 6C) was increased by MYC
expression to such a degree that animals had to be sacrificed after
six weeks. In spite of this limited time span of the experiment,
metastasis to lung and liver was observed at low frequency
(Figure 6 D and 6E). Analysis of lung sections from A-549 J5-1
cells inoculated mice showed expression of chicken MYC in lung
metastasis confirming the origin of cells (Figure S10). The
combined data establish c-MYC as a strong metastasis inducing
gene for NSCLC.
Use of mutations in primary tumors of SpC-c-MYC single
transgenic mice for lineage tracing of metastasis
The discovery of frequent K-Ras and LKB1 mutations in lung
tumors primarily of SpC-c-MYC single transgenic mice suggested
that we might be able to use mutation data for lineage tracing. We
therefore examined the DNA of liver and lymph node metastases
for the mutations present in the primary tumors. Surprisingly in
case of K-Ras mutations, four out of the five cases of c-MYC tumor
derived metastases that could be examined in this way were
negative for the mutation as was the one case of a compound
mouse that had a K-Ras exon 1 mutation in the primary tumor and
metastasis to lymph nodes (Figure 5B). However one out of the five
cases of K-Ras positive c-MYC tumor derived metastasis was
positive for mutant K-Ras. The mutation was identical to that in
the lung tumor. This mouse had multiple organ metastases that
included besides liver, kidney, pancreas and brain. Moreover,
metastasis at different sites shared expression of lung markers.
Figure S11 shows that scattered pro SP-C positive cells are present
in distant metastasis in liver, pancreas, brain and kidney.
Additionally in the kidney, Clara cell secretory protein (CCSP)
positive tumor cells were detected (Figure S11). In the one case of a
LKB1-mutant lung tumor that gave rise to liver metastasis, the
metastasis scored negative for the mutation. The fact that
mutations present in the primary lung tumors are mostly absent
in their liver metastases strongly suggests that metastasis is an early
event.
Histopathology of metastasis from SpC-c-MYC single
transgenic and compound mice
On histopathological examination metastases of both genotypes
were indistinguishable except for their abundance (Figure 4A and
Figure 5A). In both cases we find two types of metastasis in liver
and lymph nodes, papillary and mixed cystic-papillary (Figure 4B).
Commonly both forms coexist in the same target organ (Figure
S12). Whether these two forms can interconvert or whether cysts
are early precursor forms of mixed cystic-papillary metastasis is
currently unknown. However the fact that we found one example
of purely cystic liver metastasis which shows scattered pro SP-C
positive cells in the lining epithelium (Figure S13) may argue that
cysts may be a transitional state to development of frank
malignancy.
C-RAF and c-MYC transgene expression was readily detected
in liver metastasis (Figure S14). Whereas liver metastasis retained
heterogeneous expression of pan-Cytokeratin, TTF-1 and pro SP-
C, no pro SP-C expression was detected in lymph node metastasis
indicating a more immature phenotype (Figure 4C). CCSP
expression was not a uniform feature of liver metastasis of either
genotype (data not shown). However there were positive cases with
abundant expression (Figure S15A). This finding provided us with
the opportunity to test for the presence of BASCs by searching for
co-expression of pro SP-C and CCSP. Yet, attempts to detect
double positive BASC cells in this metastasis were negative (Figure
S15B) suggesting that CCSP positive cells may have been
generated by multipotent cells without BASCs as intermediates.
We therefore evaluated additional progenitor markers/lineage
selectors for expression in tumor tissue of metastasis prone mice.
Genes were selected based on their role during lung development
and expression in emerging lung foci from compound mice.
Candidates included Gata family members Gata6 and Gata4,
Aquaporin 5, Id2 and PGP 9.5. The Gata6-Wnt pathway was
recently shown to be required for epithelial stem cell development
and airway regeneration [38]. Gata4 on the other hand is involved
in maintenance of intestine in adult mice. Gata6 expression
gradually decreased as a function of age in SpC-c-MYC single
transgenic and compound mice in primary tumor (Figure S16A)
and liver metastasis (Figure 7). Concomitantly strong nuclear
Gata4 expression was detected in lung tumors (Figure S16A) as
early as six months of age (Figure S17A) and their liver metastasis
(Figure 7). In contrast, lung tumors of SpC-C-RAF BxB that are
marked by stable Gata6 expression and remain Gata4 negative
(Figure S16A). Mucin is a target gene of Gata4 in the intestine
[39]. To establish functionality of ectopically expressed Gata4 in
lung cells, we stained the primary lung tumors and liver metastases
for mucin expression. Remarkably primary tumors and metastasis
with columnar cells stained positive (Figure S16B and Figure 7)
whereas tumors with cuboidal morphology were negative both in
lungs of single SpC-C-RAF BxB transgenic and compound mice
(Figure S16B). As an extension of these experiments we have
examined whether Gata4 expression occurred at the expense of
Gata6 and pro SP-C. As expected for a lineage switch process,
large areas of mutually exclusive expression were found (Figure
S17B). Another selector gene that marks intestinal lineages, Cdx2
was not expressed in primary tumors or metastasis of any of the
genotypes (data not shown) highlighting Gata4 as a specific MYC
target. Aquaporin 5 which was also detected in early expanding
foci in the lung was strongly positive in liver metastasis (Figure 7).
Finally PGP 9.5 which we have identified as a novel marker for
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tumor vasculature in mouse NSCLC was highly expressed in the
vasculature of liver metastases (Figure 7). These markers may
therefore be suitable for early detection of metastases of NSCLC.
Human liver metastasis recapitulates the salient features
of metastasis in the mouse
Mouse tumors do not always phenocopy their human correlates.
It was therefore important to test whether changes observed
during metastatic progression in the mouse also exist in human
disease. Biopsy sections of liver metastasis from patients with
NSCLC were first stained for the panel of markers found to be
positive in mouse primary lung tumors and their corresponding
liver metastasis. For control a primary tumor and the correspond-
ing liver metastasis from stomach, a human tissue that normally
expresses Gata4 was included.
As evident from Figure 7, there is a direct correspondence in
Gata expression in the samples of both species. Three out of three
liver metastasis of human NSCLC expressed Gata4 as illustrated
in Figure 7 panel two. Expression of Gata4 is not as strongly
confined to the nucleus as in the gastric liver metastasis (Figure 7
panel 3). The same pattern observed for Gata4 expression in
human lung- to liver- metastasis is seen in the Alcian Blue 2.5
staining that identifies mucins emphasising the functionality of
Gata4 (Figure 7). Gata6 expression in human lung- to liver-
metastases shows a mutually exclusive pattern to Gata4 (Figure 7).
We next stained the human liver metastases sections with
Aquaporin 5. Aquaporin 5 staining is only present in mouse and
human liver metastases that originate from lung. There was no
staining of the human gastric- to liver- metastasis (Figure 7). This
marker may therefore be suitable for early detection of metastases
of NSCLC. The lung progenitor cell marker Id2 that was
expressed in emerging foci from compound mice (Figure S5) was
also present in human liver metastases independent of lung or
gastric origin. Finally PGP 9.5 which we have identified as a novel
marker for tumor vasculature in mouse NSCLC was highly
expressed in human lung to liver metastases exclusively in tumor
cells whereas tumor cells in human gastric to liver metastases were
negative (Figure 7).
Discussion
Here we have identified c-MYC as a metastasis inducer in a
mouse model for NSCLC. Importantly these findings are not
limited to mouse as the switch to metastasis was also observed in
the human NSCLC cell line A-549 upon infection with MYC
virus. We have used this model to identify novel markers for
diagnosis of human lung to liver metastasis. The nature of these
markers suggests that a lineage switch mechanism may be involved
in progression to metastasis.
c-MYC induces metastases
In our RAF-driven murine lung cancer model that does not
progress spontaneously to an invasive or metastatic phenotype, we
have shown previously that disruption of E-cadherin promotes
progression to metastasis. Although accumulation of nuclear ß-
catenin and up-regulation of c-MYC RNA occurred under these
conditions, metastasis was limited to micrometastasis after a long
latency period and did not include accumulation of nuclear c-
MYC [11] and data not shown). In contrast, we show here for the
first time that forced constitutive or inducible expression of nuclear
c-MYC is sufficient to induce early macrometastasis of RAF-
driven-NSCLC indicating that the level of c-MYC expression is a
major determinant in this process. Metastasis was not described in
the earliest report on oncogene transgenic mice utilizing c-MYC
for induction of breast carcinoma [40] and pancreatic carcinoma
[41]. Only recently a metastatic phenotype was reported for Ela-
myc single and for MT-tgfa/Ela-myc double transgenic mice that
gave rise to peritoneal and liver metastasis at an advanced stage
[42]. More recently the role of c-MYC in mouse models of
NSCLC was evaluated [18,19,43]. Even though c-MYC was
shown to strongly cooperate with K-Ras in lung tumor
progression, the role of c-MYC in this process could not be
evaluated as neither model gave rise to metastasis. Why did these
experimental strategies not reveal a metastasis function of c-MYC?
There are major differences when compared to our model. First in
the study that is most similar to ours as it used an inducible
promoter and allowed for long term expression of c-MYC, a Clara
cell specific- (CCSP) rather than alveolar type II cell specific-
promoter (SpC) was used. This difference not only affects
expression levels but examines c-MYC in different cells of origin
of NSCLC (Clara cells instead of type II pneumocytes) and
therefore may represent a different transformation pathway. The
major difference of the second study relative to our work is the
short term induction that for technical reasons was followed only
for seven weeks. Furthermore in this study K-Ras was used instead
of oncogenic C-RAF. The paucity of mutant K-Ras in liver
metastases in our system may suggest that RAF is a stronger
cooperation partner of MYC for metastatic progression perhaps
because of differences in target cell specificity for transformation.
In any case the model presented by us is highly robust and mimics
the patterns observed for metastasis of human NSCLC.
c-MYC requires cooperation with C-RAF, K-Ras or LKB1 in
lung tumor progression
In our mouse NSCLC model, c-MYC alone was incapable of
productive transformation let alone metastasis as its deleterious
effects on cell survival blocked expansion of initiated cells. Only
pockets of pleomorphic cells were present throughout the latency
period. These clusters are potential targets for progression by
secondary genetic events and therefore may have prognostic
significance as premalignant lesions. In fact examination of long
term survivors in the cohorts of SpC-c-MYC single transgenic
mice showed lower abundance and in some cases lack of these
premalignant lesions. Cells in these lesions differ from normal type
II cells as they express high levels of c-MYC and its target Id2 [26]
which is thought to mark multipotent lung progenitors during
embryonic development [20]. Decreased levels of SpC expression
Figure 6. Increased tumor growth and rapid induction of metastatic switch in human A-549 cells by MYC. (A) Immunofluorescence
staining of A-549 cells infected with chicken v-myc expressing J5 virus shows MYC (red) expression. Dapi marks nuclei. Scale bar: 50 mm. (B) Tumor
incidence of control and MYC expressing A-549 cells six weeks after subcutaneous injection. Animal numbers (n) are as indicated. (C) Monitoring of
tumor growth during six weeks of period. Tumors were measured weekly. MYC expressing cells gave rise to statistically larger tumors in Rag12/2
mice. Values represent SD of the mean. *: p,0.05. n = 17 mice for each group. (D) Analysis of metastases. Paraffin embedded sections of lung, lymph
node and liver tissues from transplanted mice were screened for metastasis by using cytokeratin-7 (CK-7) antibody. To demonstrate specificity of CK-7
expression in A-549 cells primary tumors were stained in the absence (negative control) or in the presence (positive control) of CK 7 antibody. For
each organ at least 3 sections were stained and carefully screened at least by two persons. n = 17 mice for each group. Scale bar: 50 mm. (E) Incidence
of Metastasis. L.N: Lymph node.
doi:10.1371/journal.pone.0006029.g006
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Figure 7. Human liver metastasis recapitulates the salient features of metastasis of mouse NSCLC. Paraffin embedded human liver biopsy
sections were stained as indicated. L: liver, M: metastasis. Liver metastasis from lung and gastric cancers were compared. The lower of the two Aquaporin
5 panels is the higher magnification of the yellow boxes. Blue inset shows normal human liver that is negative for Aquaporin 5. Scale Bar: 100 mm.
doi:10.1371/journal.pone.0006029.g007
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in these cells are consistent with such a phenotype as the Myc
effector Id2 is known to interfere with differentiation [44].
C-RAF cooperates with c-MYC in tumor progression by
suppressing apoptosis. Alternatively c-MYC can be complemented
by activation of K-Ras or LKB1. A second consequence of
cooperation between these oncogenes is induction of a new
alveolar papillary epithelial cell type, APEC. Induction of APECs
is rapid and affects a large fraction of cells. These cells have the
highest proliferation index in primary lung tumors and form the
predominant cell type found in solid metastasis. Kinetic analysis of
this switch strongly suggests epigenetic mechanisms as opposed to
a mutation driven process as they arise rapidly and at high
frequency. Marker gene expression indicates that the columnar
cells are different from cells that were previously associated with
lung cancer stem cells, BASC [23], or regeneration in the lung, i.e.
variant clara cells [45] because they express Aquaporin 5 and are
negative for CCSP. Moreover BASCs are not likely to be involved
in metastasis because they are not detectable in late metastasis
even when pro SP-C positive and CCSP positive single cells are
abundant (Figure S14).
A similar phenotypic switch from cuboidal to columnar cells has
been seen before upon deletion of p53 in SpC-C-RAF BxB
transgenic mice [46] although at much lower frequency than in C-
RAF/c-MYC compound mice. Since p53 has been reported to
transcriptionally repress c-MYC [47] the simplest explanation for
the earlier findings would be c-MYC up-regulation. Although the
columnar cell switch is uniformly seen in compound and single
transgenic mice only a fraction of them precedes to generate
metastasis. Therefore we have to consider that additional events
are required for the metastasis switch.
Evidence for early generation of multipotent metastasis-
initiating cells (MICs)
The earliest metastatic lesions in the liver of mice of any
genotype were observed at ten months. At this time, the largest
liver metastasis was larger than 5 grams and consisted of dozens of
individual tumor foci. This observation provides the strongest
argument for spread of MICs very early in the disease, perhaps as
early as three to five months. Unfortunately detection of isolated
seed cells in the liver was beyond our capacity because full
examination would have required microscopic examination of
thousands of sections. There are additional observations that
support an early dissemination scenario. These include lack of
secondary mutations in the majority of the metastasis, suggesting
that premalignant pleomorphic clusters in SpC-c-MYC lungs
might give rise to MICs. Moreover there were several examples
with large metastasis in the liver and small tumor mass in the lung
consistent with seeding of the liver at an early stage of tumor
development. Finally the ability to convert A-549 human NSCLC
cells to metastasising cells by forced MYC expression now enables
us to study the sequence of events required for this switch in
phenotype.
Angiogenic switch induction by c-MYC
In addition to promoting an immature phenotype of tumor cells
c-MYC accelerates growth of primary tumors by induction of
angiogenesis. The ability of c-MYC to induce angiogenesis has
been observed previously in other tumor models. In the pancreas a
mechanism was delineated which involves mast cells [17]. In our
mouse model for NSCLC we could not find any mast cells in the
primary tumors or metastases (data not shown). On the other
hand, MYC has been shown to induce angiogenesis in conjunction
with HIF1 alpha by means of VEGF in lymphomas and epidermal
lesions [31,48]. In fact we did observe VEGF expression in our
Myc expressing primary lung tumors and clones of Myc virus
infected human A-549 and mouse MLE-15 NSCLC cells (Figure
S7) extending these earlier findings to the lung.
In the course of examining tumors for expression of neuroen-
docrine function, we surprisingly detected high amounts of PGP
9.5 positive cells mainly in tumor vasculature. This pattern of
expression was also found in the liver metastasis of mice as well as
in normal large vessels. Interestingly PGP 9.5 was previously
shown to be expressed by tumor cells in human NSCLC where it is
used as a prognostic marker [32]. Based on the PGP 9.5 expression
in normal human endothelial cells, the discrepancy between PGP
9.5 localisation might suggests that tumor cells can give rise to
endothelial cells. In this case we would expect the PGP 9.5 positive
endothelial cells of the tumor vasculature to also be positive for
mutations present in the primary tumor. Future experiments will
clarify this issue.
Expression of novel markers in human lung to liver
metastases
In order to evaluate relevance of our findings to human
pathology, we have typed biopsy samples from human liver
metastases for expression of our newly found markers of
metastases. The pattern of Gata6, Gata4 and its target mucin as
well as Id2 paralleled our findings in the mouse. Importantly
Aquaporin 5 and PGP 9.5 expressions were unique to liver
metastases from human NSCLC suggesting their usefulness for
discrimination between tissues of origin. These findings also
suggest that lineage switch events such as the Gata6-Gata4
exchange may drive progression to metastasis of NSCLC in mouse
and man [14,15]. Finally as Gata4 is dispensable for integrity of
the adult lung, it may be an ideal target for development of future
treatment regimens to treat lung cancer provided that therapy can
be targeted to lung.
Materials and Methods
Animals
All animal studies were approved by the Bavarian State
authorities for animal experimentation. Mice were housed under
barrier condition in air-filtered, temperature-controlled units with
a 12 h light/dark cycle with free access to food and water. Mice
were monitored for signs of respiratory distress by inspection of
their mobility and sacrificed before signs of extensive respiratory
distress. All mice were of similar genetic background ($90%
C57Bl/6, #10% FVB/n) and maintained as heterozygotes.
Compound mice were obtained by intercrossing heterozygotes.
Other details of transgenic mice are described in Supporting
Information (Text S1).
RNA isolation and RT-PCR analysis
Semi quantitative RT-PCR was performed on total lung RNAs
extracted from 6 weeks old mice using TRIZOL (Invitrogen)
reagent as previously described ([11]. Oligos for human MYC
sense: 59- TTC CCC TAC CCT CTC AAC GAC AG – 39and
human MYC anti-sense: 59- TCC TTA CTT TTC CTT ACG
CAC AA- 39were used for amplification of human c-MYC. Actin
was used for loading control.
In vivo bioluminescence imaging
Bioluminescence imaging of luciferase expression in compound
mice (SpC-C-RAF BxB/SpC-rtTA/tet-O-c-MYC) was performed
as described [49]. Briefly, mice were anesthetized with ketamine/
rompun and subsequently received an i.p. injection of an aqueous
solution of the substrate D-luciferin (125 mg/kg). The animals
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were then placed in a light-tight chamber and imaged with a
CCCD camera. Images were acquired 20 minutes after luciferin
administration. Signal intensity was quantified as the sum of all
detected photon counts within the region of interest after
subtraction of background luminescence.
Immunofluorescence and Immunohistochemistry
Microscopy
Animals were sacrificed and organs were fixed with 4% PBS
buffered formalin. Histology was done on formalin-fixed, paraffin-
embedded lung specimen. 6 mm-cut sections were deparaffinized,
rehydrated in graded alcohols and haematoxylin-eosin stained.
Details of staining protocols are given in Supporting Information
(Text S1).
Histopathology
Preparations of embedded tissues and quantitative assays for
lung tumor development are described in Supporting Information
(Text S1).
Statistical analysis. Tumour-free survival and comparisons
of tumour numbers and tumour volume were analysed using
GraphPad Prism4 software. Data are presented as mean6s.e.m.
Student’s t test (two-tailed) was used to compare two groups
(P,0.05 was considered significant).
Supplemental Data
Supplemental data include Supporting Information, 17 figures
and one table.
Supporting Information
Text S1 Supporting Material Methods and Supplementary
figure legends
Found at: doi:10.1371/journal.pone.0006029.s001 (0.16 MB
DOC)
Figure S1 Premalignant lesions of SpC-c-MYC mice express
type II pneumocyte- and progenitor- cell markers. Paraffin
embedded lung sections were stained as indicated. Clusters of
pleomorphic cells that represent premalignant lesions in SpC-c-
MYC mice were highlighted with red circles. Scale bar: 50 mm.
Found at: doi:10.1371/journal.pone.0006029.s002 (7.93 MB TIF)
Figure S2 Rescue of cryptic MYC transformants by co-
expression of RAF. (A) Paraffin embedded lung sections from all
genotypes were stained for active caspase 3 (brown) to detect
apoptotic cells. Yellow circles identify neoplastic lesions. Jurkat
cells treated or untreated with etoposide were used as positive and
negative control, respectively. Haematoxylin (Blue) was used for
counterstaining. Scale bar: 50 mm. (B) Quantitation of apoptotic
cells for indicated genotypes. At least 40 randomly selected lesions
from 3 mice per genotype were analysed for quantitation of
apoptotic cells.
Found at: doi:10.1371/journal.pone.0006029.s003 (2.28 MB TIF)
Figure S3 Conditional expression of c-MYC in lung alveolar
type II cells induces tissue destruction. (A) Schematic diagram
showing the generation of compound (SpC-rtTA/tet-O-c-MYC)
mice conditionally expressing c-MYC in type II pneumocytes. Hs:
Human. (B) Semi-quantitative RT-PCR showing inducible
transgenic c-MYC (human) expression in lungs of compound
mice after one week DOX administration. (C) Lung of a
compound (SpC-rtTA/tet-O-c-MYC) mouse after four weeks
induction shows severe tissue loss (white arrows) as evident from
inspection of whole lung and the H&E stained section. Active
caspase 3 staining identifies apoptotic cells (brown cells indicated
by red arrows) in alveoli one day after doxycycline administration.
Haematoxylin (blue) was used for counterstaining. (D) H&E
staining of a lung section from four weeks-induced compound
(SpC-rtTA/tet-O-c-MYC) mouse shows isolated pleomorphic cell
clusters (yellow dash marking). (E) H&E staining of a lung section
from 26 weeks-induced compound (SpC-rtTA/tet-O-c-MYC)
mouse shows a lung adenocarcinoma with columnar cells. Scale
bar: 100 mm.
Found at: doi:10.1371/journal.pone.0006029.s004 (3.53 MB TIF)
Figure S4 Induction of phenotypic switch from cuboidal to
alveolar papillary/columnar epithelial cells (APECs). (A) H&E
staining of a mixed (cuboidal and columnar) lung tumor section
from four months old compound (SpC-C-RAF BxB/SpC-c-MYC)
mouse. (B) Schematic diagram showing the generation of triple
transgenic compound (SpC-C-RAF BxB/SpC-rtTA/tetO-c-
MYC) mice. (C) H&E staining of lung tumor sections from
inducible (SpC-C-RAF BxB/SpC-rtTA/tetO-c-MYC) compound
mice shows the kinetics of columnar cell appearance. D: day, W:
week, M: month. Right hand panel is a magnification of the yellow
box. Scale bar: 100 mm. (D) Six weeks old compound mice were
imaged for in vivo luciferase expression following one week On
DOX/4 weeks Off DOX schedule demonstrating inducibility.
H&E staining of a lung tumor section of the On/Off DOX mouse.
Inset highlights persistent papillary tumor area indicated by yellow
box.
Found at: doi:10.1371/journal.pone.0006029.s005 (3.75 MB TIF)
Figure S5 Immunostaining of emerging and late tumors of
compound mice (SpC-C-RAF BxB/SpC-c-MYC) for lineage and
progenitor cell markers. (A) Emerging tumors from 2 weeks-old
mice were stained as indicated. (B) Late tumors from 10–16
months-old mice were stained as indicated. Markers are as
indicated. In the case of fluorescence stainings colours correspond
to the indicated proteins. Dapi (blue) illustrates nuclei. (C) b-
catenin (green) staining of a lung tumor showing membrane
localisation. Dapi (blue) illustrates nuclei.
Found at: doi:10.1371/journal.pone.0006029.s006 (7.15 MB TIF)
Figure S6 Induction of angiogenic switch by c-MYC. (A)
Immunostaining of lung tumor sections from control and
metastatic animals of indicated genotypes for blood (Pecam 1)
and lymph (Prox 1) vessels. Scale bar 100 mm. (B, C) Quantitation
of vessel density. 5 mice per genotype were analysed. Values
represent SD of mean. P values are as indicated. (D) PGP 9.5
immunostaining of lung tumor sections. Scale bar 100 mm. (E)
Frozen lung sections from wild type (wt) and compound mice were
stained for PGP 9.5 (red) and PECAM-1 (green) for co-expression.
Dapi illustrates nuclei. Scale bar 50 mm.
Found at: doi:10.1371/journal.pone.0006029.s007 (5.74 MB TIF)
Figure S7 VEGF induction by MYC in primary lung tumors
and NSCLC cell lines. (A) Immunostaining of lung tumor sections
from age-matched mice of the indicated genotypes for VEGF
(brown). Haematoxylin (blue) was used for counterstaining. Scale
bar: 100 mm. (B) Immunocytochemistry of human A-549 and
mouse MLE-15 NSCLC cell lines for VEGF (green). Note
increased VEGF expression in cells infected with Myc expressing
retroviruses J5-1 and J2-11. One representative cell clone is shown
for each virus. Dapi (blue) illustrates nuclei. Scale bar: 10 mm.
Found at: doi:10.1371/journal.pone.0006029.s008 (3.77 MB TIF)
Figure S8 No evidence for EMT in tumor progression. (A) E-
cadherin immunofluorescence staining (brown) of lung tumor
section from a 12 months old compound mouse. Scale bar:
100 mm. (B) Paraffin embedded lung tumor sections from control
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and metastatic animals were stained for EMT markers as
indicated. Tumor cells were marked by pro SP-C (green) staining.
Dapi (blue) illustrates nuclei. Scale bar: 100 mm.
Found at: doi:10.1371/journal.pone.0006029.s009 (3.53 MB TIF)
Figure S9 Inducible expression of c-MYC in SpC-C-RAF BxB
lung tumors give rise to liver metastasis with APECs. (A) H&E
staining of a lung section from a seven months induced compound
mouse shows large lung tumors with columnar cell. Scale bar:
100 mm. (B) Pan-cytokeratin staining (brown) of a regional lymph
node section from eleven months-induced compound mouse (SpC-
C-RAF BxB/SpC-rtTA/tet-O-c-MYC) shows micrometastasis.
(C) Inspection of a liver from a seven months induced compound
(SpC-C-RAF BxB/SpC-rtTA/tet-O-c-MYC) mouse shows a
tumor nodule in the liver (red circle). (D) H&E staining of the
liver metastasis shown in C demonstrates papillary tumors with
stroma (S). Scale bar: 100 mm. (E, F) Pan-cytokeratin (E) and pro
SP-C immunostaining of the liver metastasis shown in C. Isolated
pan-cytokeratin and pro SP-C positive tumor cells that were
embedded in the stroma (S) were indicated by red arrows.
Found at: doi:10.1371/journal.pone.0006029.s010 (6.17 MB TIF)
Figure S10 Staining of primary tumor and lung metastasis
developing after subcutenous injection of A-549 J5-1 cells for
chicken c-MYC.
Found at: doi:10.1371/journal.pone.0006029.s011 (3.35 MB TIF)
Figure S11 Histopathology of metastasis to distant organs in old
SpC-c-MYC mice. Multiple target organs are involved in case of a
mutant K-Ras positive SpC-c-MYC lung tumor at age 20,5
months. Tissue sections were stained with indicated markers which
identifies derivation of metastasis from lung adenocarcinoma.
Haematoxylin (blue) was used for counterstaining.
Found at: doi:10.1371/journal.pone.0006029.s012 (3.71 MB TIF)
Figure S12 Cystic and papillary forms coexist in late liver
metastasis. (A) Macroscopic liver metastasis in an 18 months old
SpC-c-MYC mouse. Note multiple solid tumor nodules (papillary,
black arrows) and cystic lesion (yellow arrow). (B) H&E staining of
liver metastasis confirm coexistence of both papillary and cystic
(yellow circle) lesions in the same organ.
Found at: doi:10.1371/journal.pone.0006029.s013 (2.83 MB TIF)
Figure S13 Cystic liver metastasis of a 13 months old SpC-c-
MYC mouse. High magnification of red inset illustrates presence
of pro SP-C positive (brown) cells (arrows) in the epithelial layer
lining the cyst. Haematoxylin (blue) was used for counterstaining.
Found at: doi:10.1371/journal.pone.0006029.s014 (1.35 MB TIF)
Figure S14 Expression of transgene markers in liver metastases.
Immunofluorescence staining of papillary lung tumors and liver
metastasis for expression of C-RAF (green) and c-MYC (red)
transgenes.
Found at: doi:10.1371/journal.pone.0006029.s015 (1.36 MB TIF)
Figure S15 No evidence for BASC in liver metastasis. (A)
Paraffin embedded sections from 18 months liver metastasis were
stained for CCSP and pro SP-C. Haematoxylin was used for
counterstaining. Scale bar: 50 mm. (B) The same sections were
subsequently examined for co-expression of CCSP (green) and pro
SP-C (red) to search for BASCs. Dapi (blue) illustrates nuclei.
Found at: doi:10.1371/journal.pone.0006029.s016 (3.65 MB TIF)
Figure S16 Gata6/Gata4 switch in SpC-c-MYC and compound
mice. (A) Reciprocal expression of Gata4 and Gata6 in primary
tumor of SpC-c-MYC and compound mice. Stainings as
indicated. Note decrease in the level of Gata6 expression
concomitant with heterogenous Gata4 expression in late stage
lung tumors. Duodenum and embryonic lung sections were used
for positive control for Gata4 and Gata6, respectively. (B) Alcian
Blue 2.5 expression in lung tumors from indicated genotypes.
Sections from 12 months old mice were stained with Alcian Blue
for mucin secretion (blue stains, indicated by arrows).
Found at: doi:10.1371/journal.pone.0006029.s017 (6.04 MB TIF)
Figure S17 Early and mutually exclusive expression of ectopic
Gata4. (A) A representative lung section from a six-months-old
compound (SpC-C-RAF BxB/SpC-c-MYC) mouse with an array
of Gata4 expressing (brown) cells. (B) Immunohistochemistry for
Gata4 and pro SP-C in serial sections of a lung tumor from a 18-
monthd-old SpC-c-MYC single transgenic mouse illustrating
mutually exclusive expression of both markers.
Found at: doi:10.1371/journal.pone.0006029.s018 (2.63 MB TIF)
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